Tags: Drug.

Vorapaxar (formerly SCH 530348) is a thrombin receptor (protease-activated receptor PAR-1) antagonist based on the natural product himbacine. Discovered by Schering-Plough and currently being developed by Merck & Co. it is an experimental pharmaceutical treatment for acute coronary syndrome chest pain caused by coronary artery disease.In January 2011 clinical trials being conducted by Merck were halted for patients with stroke and mild heart conditions.

SCH-530348.png
ATC prefix
none
CAS number
618385-01-6
FDA UNII code
ZCE93644N2
IUPAC name
Ethyl N-[(3R3aS4S4aR7R8aR9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a44a56788a99a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamate
PubChem
10077130

Loading...

This page contains content from the copyrighted Wikipedia article "Vorapaxar"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.